Clinical efficacy and safety of ultrasound-guided percutaneous injection of laurylalcohol foam sclerotherapy in the treatment of lymphatic malformations in children
Clinical efficacy and safety of ultrasound-guided percutaneous injection of laurylalcohol foam sclerotherapy in the treatment of lymphatic malformations in children
Objective To investigate the clinical effect and safety of ultrasound-guided percutaneous injection of laurylalco-hol foam sclerosing agent in the treatment of lymphatic malformations(LMs)in children.Methods The clinical data of 25 chil-dren with lymphatic malformations treated with ultrasound-guided percutaneous injection of laurylalcohol foam sclerosing agent were retrospectively analyzed in our hospital.The foam sclerosing agent was injected under real-time ultrasound monitoring after extraction of cystic fluid in macrocystic lesions,while,microcystic lesions were injected with foam sclerosing agent directly un-der ultrasound guidance in a diffuse manner.Clinical manifestations and postoperative ultrasound or magnetic resonance imaging results were used as indicators for efficacy assessment.Results Of the 25 cases(12 males and 13 females)with lymphatic mal-formations,12 cases were macrocystic LMs,11 cases were mixed LMs,and 2 cases were microcystic LMs,with a mean number of treatments of 1.4.All patients were followed up for 6～12 months,there were 18 cases with obvious effects and 4 cases with ef-fective effects,with a treatment effectiveness rate of 88%;3 cases of LMs(2 mixed and 1 microcystic LMs)failed to improve clinically,and 1 case appeared swelling due to combining intracapsular hemorrhage,which subsided on its own.No serious com-plications such as ulceration,pain,infection and dysfunction occurred in any of the pediatric patients.Notably,17 cases of LMs achieved effective remission in a single treatment.Conclusion Ultrasound-guided percutaneous injection of laurylalcohol foam sclerotherapy is safe and effective in the treatment of LMs in children with satisfactory cosmetic recovery,which can be used as the primary treatment for macrocystic and mixed LMs.
维普
万方数据